StrokeDETECT-ChinaNCT04752735
Endovascular treatmenT for Acute Ischemic Stroke in China
An observational study of Stroke and Endovascular Treatment, run by General Hospital of Shenyang Military Region at 1 site in China.
Trial summary
This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Endovascular Treatment
- What is being tested?
- endovascular treatment
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 22 Mar 2021to 8 Feb 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: all patients must receive endovascular treatment regardless of the time from onset to treatment.
Who may be able to join
- Age: ≥ 18;
- Ischemic stroke confirmed by head CT or MRI;
- Patients receiving endovascular treatment;
- First ever stroke or mRS≤2 after previous disease;
- Complete and clear pre- and post-operative DSA images are available
Who cannot join
- Imaging data not qualified for evaluation;
- Absence of important clinical data;
- The first 50 patients receiving endovascular treatment in a single centerr.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, 110016
About this study
Official title: Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study
This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.
- Conditions
- Stroke, Endovascular Treatment
- Being tested
- endovascular treatment
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endovascular treatmentOther
all enrolled patients must receive endovascular treatment.
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with modified Rankin Score (mRS) 0 to 2
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
Measured: Day 90
Secondary outcomes (7)
Changes in National Institute of Health stroke scale (NIHSS)
the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome
Measured: Day 2, 7, 14
Proportion of patients with modified Rankin Score 0 to 2
Proportion of patients with modified Rankin Score 0 to 2
Measured: Day180, 360
Distribution of modified Rankin Score
Distribution of modified Rankin Score after treatment
Measured: Day 90, 180, 360
Proportion of symptomatic intracranial hemorrhage (sICH)
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Measured: 48 hours
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment
Measured: 48 hours
Proportion of death
death due to any cause
Measured: Day 7
Changes in cerebral edema
edema is determined by middle shift.
Measured: 48 hours, 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2021
- Study start22 Mar 2021
- Primary completion8 Feb 2023
- Study completion8 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- General Hospital of Shenyang Military Region
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hui-Sheng Chen, General Hospital of Shenyang Military Region
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04752735
- Sponsor's protocol ID
- y (2021)013
- Acronym
- DETECT-China
- Status last verified
- Feb 2023
- First submitted
- 10 Feb 2021
- Last updated
- 10 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Xing GP, Li W, Cui C, Zhao ZA, Nguyen TN, Chen HS. Thrombolysis to Recanalization Time Affects the Benefit of Bridging Thrombolysis in Large Vessel Occlusion Patients With Successful Recanalization. CNS Neurosci Ther. 2025 Sep;31(9):e70579. doi: 10.1111/cns.70579.
PubMed 40947819
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study
- ClinicalTrials.gov ID
- NCT04752735
- Acronym / sponsor ID
- DETECT-China / y (2021)013
- Conditions
- Stroke, Endovascular Treatment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- General Hospital of Shenyang Military RegionUniversity, hospital or other
- Study start
- 22 Mar 2021 (actual)
- Primary completion
- 8 Feb 2023 (actual)
- Study completion
- 8 Feb 2023 (actual)
- First posted
- 12 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- all patients must receive endovascular treatment regardless of the time from onset to treatment.
Key inclusion criteria (5 listed)
- Age: ≥ 18;
- Ischemic stroke confirmed by head CT or MRI;
- Patients receiving endovascular treatment;
- First ever stroke or mRS≤2 after previous disease;
- Complete and clear pre- and post-operative DSA images are available
Key exclusion criteria (3 listed)
- Imaging data not qualified for evaluation;
- Absence of important clinical data;
- The first 50 patients receiving endovascular treatment in a single centerr.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endovascular treatmentall enrolled patients must receive endovascular treatment. | Other | – |
Primary outcome
Proportion of patients with modified Rankin Score (mRS) 0 to 2
Time frame: Day 90
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
7 secondary outcomes
Changes in National Institute of Health stroke scale (NIHSS)
Time frame: Day 2, 7, 14
Proportion of patients with modified Rankin Score 0 to 2
Time frame: Day180, 360
Distribution of modified Rankin Score
Time frame: Day 90, 180, 360
Proportion of symptomatic intracranial hemorrhage (sICH)
Time frame: 48 hours
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time frame: 48 hours
Proportion of death
Time frame: Day 7
Changes in cerebral edema
Time frame: 48 hours, 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2023.
- Derived from this study: PubMed 40947819Xing GP, Li W, Cui C, Zhao ZA, Nguyen TN, Chen HS. Thrombolysis to Recanalization Time Affects the Benefit of Bridging Thrombolysis in Large Vessel Occlusion Patients With Successful Recanalization. CNS Neurosci Ther. 2025 Sep;31(9):e70579. doi: 10.1111/cns.70579.
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke and Endovascular Treatment, run by General Hospital of Shenyang Military Region at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with modified Rankin Score (mRS) 0 to 2 (time frame: Day 90). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04752735, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2023.